IP Library Granted Patent US 8,618,099
Granted Patent B2
US 8,618,099 · App. 13/061,347 · Granted Dec 31, 2013

Pyrazolyl-pyrimidine derivatives and their use as potassium channel modulators

Inventors: Birgitte L. Eriksen (Farum, DK); Charlotte Hougaard (Bagsværd, DK); Dan Peters (Malmö, SE); Palle Christophersen (Ballerup, DK)
Assignee: Ataxion, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,618,099
App. No.
13/061,347
Granted
Dec 31, 2013
Kind
B2
Abstract

This invention relates to novel pyrazolyl-pyrimidine derivatives and their use as potassium channel modulating agents. In another aspect the invention is directed to pharmaceutical compositions useful for the treatment or alleviation of diseases or disorders associated with the activity of potassium channels.

Claims (11)

1. A compound of formula (I)

or a pharmaceutically acceptable salt thereof, wherein

R 1 represents phenyl or indanyl, which phenyl is optionally substituted with one or more substituents independently selected from alkyl and halo; and

one of R 2 , R 3 and R 4 represent hydrogen; and the other two of R 2 , R 3 , and R 4 represent alkyl.

2. The compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 represents phenyl which is optionally substituted with halo.

3. The compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 represents indanyl.

4. The compound of claim 1 , which is:

(4-Chloro-phenyl)-[2-(3,5-dimethyl-pyrazol-1-yl)-6-morpholin-4-yl-pyrimidin-4-yl]-amine;

[2-(3,5-Dimethyl-pyrazol-1-yl)-6-morpholin-4-yl-pyrimidin-4-yl]-indan-2-yl-amine; or

or a pharmaceutically acceptable salt thereof.

5. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically-acceptable carrier or diluent.

Assignments (6)
MERGER Recorded Jul 17, 2023
From: ATAXION, INC.
To: LUC THERAPEUTICS, INC.
Reel/Frame 064277/0494 →
CHANGE OF NAME Recorded Jul 17, 2023
From: LUC THERAPEUTICS, INC.
To: CADENT THERAPEUTICS, INC.
Reel/Frame 064277/0542 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 17, 2023
From: CADENT THERAPEUTICS, INC.
To: NOVARTIS AG
Reel/Frame 064277/0562 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 6, 2013
From: ANIONA APS
To: ATAXION, INC.
Reel/Frame 030946/0329 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 20, 2013
From: NEUROSEARCH A/S
To: ANIONA APS
Reel/Frame 030049/0894 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 2, 2011
From: ERIKSEN, BIRGITTE L.; HOUGAARD, CHARLOTTE; PETERS, DAN; CHRISTOPHERSEN, PALLE
To: NEUROSEARCH A/S
Reel/Frame 026380/0957 →
Priority Claims (1)
DK 2008 01219 · Sep 2, 2008 · national
Continuity (2)
Provisional Application 61094142 · Sep 4, 2008
Related Publication 20110230484A1 · Sep 22, 2011